The Supreme Court of Canada heard oral arguments in AstraZeneca v Apotex and reserved its decision about patent utility and the ‘promise doctrine’, in a case centring on pharmaceutical company AstraZeneca’s heartburn relief drug Nexium (esomeprazole magnesium).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
AstraZeneca v Apotex, Astrazeneca, Apotex, patent, utility, gastric acid, Nexium, Supreme Court of Canada, promise doctrine,
